STAT+: Peptide market poised to explode with new Hims and Noom launches
Peptides are poised to go mainstream with this week’s launches from telehealth companies Hims & Hers and Noom, both of which announced they will be offering prescriptions for eligible patients.
- While peptide prescriptions were already offered by smaller telehealth companies, Hims (with a market cap of more than $3.5 billion) and Noom (a private company valued at $3.7 billion) are two of the industry’s dominant players, making the announcements a pivotal moment for peptides in the United States.
- Continue to STAT+ to read the full story….
- The Department of Health and Human Services, however, has foregrounded the drugs under health secretary Robert F.
Initially popular among bodybuilders, certain drugs in the class have gained traction among a broad swath of people looking to optimize their health — whether to build muscle, feel more energetic, increase libido, or recover from injuries.
- But many compounded peptides that are marketed to consumers are experimental.
- Synthetic peptides are a broad category of short-chain amino acids.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →